Marrone Bio Innovations

Marrone Bio Innovations LT Debt/Equity

Delisted

The Long-Term Debt to Equity Ratio of Marrone Bio Innovations (MBII) as of Nov 18, 2026 is 0.26. In the previous year, Long-Term Debt to Equity Ratio was 0.37 — a change of -29.03% (lower).

LT Debt/Equity

0.26

YoY

-29.03%

Last updated:

Long-Term Debt to Equity Ratio of Marrone Bio Innovations is 2021 0.26 . Long-Term Debt to Equity Ratio of Marrone Bio Innovations was 2020 0.37 . It decreases by -29.03% lower compared to the previous year.

The Marrone Bio Innovations LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2014
0.30 USD
Jan 1, 2015
-10.78 USD
Jan 1, 2016
-0.70 USD
Jan 1, 2017
-0.48 USD
Jan 1, 2018
1.48 USD
Jan 1, 2019
0.50 USD
Jan 1, 2020
0.37 USD
Jan 1, 2021
0.26 USD
The Marrone Bio Innovations LT Debt/Equity history
YEARLT Debt/EquityYoY
0.26-29.03%
0.37-27.33%
0.50-65.97%
1.48-406.72%
-0.48-31.01%
-0.70-93.52%
-10.78-3,735.59%
0.30—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Marrone Bio Innovations Stock analysis

What does Marrone Bio Innovations do? Marrone Bio Innovations Inc is an American company that has been operating in the field of biological pest control since 2006. It was founded by chemist Dr. Pamela Marrone and is headquartered in Davis, California. The company's business model is based on developing safe and effective biological pest control products made from natural ingredients. The aim is to minimize the environmental impact of agriculture. The company is divided into different divisions, including biological plant protection, biological nitrogen fixation, biological weed control, and other products. Some of the well-known products include Regalia®, Venerate®, and Majestene®. Marrone Bio Innovations has gained significance in recent years and is now one of the leading companies in the field of biological pest control. The company works closely with farmers, research institutions, and regulatory authorities to develop and introduce new products, always prioritizing safety and environmental compatibility. Marrone Bio Innovations is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Marrone Bio Innovations stock

Long-Term Debt to Equity Ratio of Marrone Bio Innovations is 0.26 in 2021.

Long-Term Debt to Equity Ratio of Marrone Bio Innovations changed from 0.37 to 0.26, representing a -29.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Marrone Bio Innovations since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Marrone Bio Innovations with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Marrone Bio Innovations

All Key Metrics — Marrone Bio Innovations